← boardnext 2027-11
SABS
SAb Biotherapeutics, Inc.distress 3/10 · well-funded / low risk$3.54-1%today-23% from 52w high
Lead: type 1 diabetes · est. market ~$70B (approx, global)
Revenue
pre-revenue
Liquidity
$218M
Runway
4.3 yrs
Shares 1y
+635%
Price & events
-11.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
-3.5%
1W
-8.7%
1M
-7.0%
3M
-12.5%
6M
+42.0%
1Y
+30.9%
2Y
-96.5%
5Y
-96.5%
All
Overview
- Market Cap
- $270.30M
- Volume
- 26.79K
- 52 Week Range
- $1.88 – $4.59
- Total Shares
- 76.46M
- Float Shares
- 41.20M
- Short %
- 5.12%
- % Held by Insiders
- 0.84%
- % Held by Institutions
- 91.93%
- RVOL
- 0.03x
- Beta
- 0.53
Pipeline stages · 2 programs
High Dose SAB-142, Low Dose SAB-142
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Single Ascending Dose of SAB-176
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-11 Estimated 50% readout ~2027-12-16 | Phase 2 | High Dose SAB-142, Low Dose SAB-142 | Type 1 Diabetes | — | recruiting |
| 2025-02-01 | Phase 1 | Single Ascending Dose of SAB-176 | PHA1A | 28 | active not recruiting |
Catalyst news & presentations · 8
- 2H 2027Guided 55%readoutPhase 2SAB-142 · Topline data from Phase 2b SAFEGUARD trialSEC 8-K
- end of 2026Guided 40%enrollment completesecondaryPhase 2SAB-142 · Complete enrollment of SAFEGUARD Phase 2b trialSEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-07-07partnershipSAB-142 · Breakthrough T1D awards grant to support PRISE-hATG study of SAB-142 in Stage 3 T1D; SAB BIO co-funds.SEC 8-K
- 2025trial initiationsecondaryPhase 2SAB-142 · Plan to initiate Phase 2b trial in 2025SEC 8-K
- 2025-01-28conferencedata presentationsecondarySAB-142 · R&D webinar to discuss resultsSEC 8-K
- by the end of 2024readoutPhase 1SAB-142 · Top-line Phase 1 data expected by end of 2024.SEC 8-K
- 2024-09-09conferencedata presentationsecondaryPhase 1SAB-142 · Progress update at EASD 60th Annual MeetingSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 76,464,094 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $11 (+216% upside) · 11 analysts
- 2026-06-24BarclaysOverweight
- 2026-06-17Chardan CapitalBuy
- 2026-06-15Leerink PartnersOutperform
- 2026-06-15HC Wainwright & Co.Buy
- 2026-05-22CitigroupBuy
- 2026-05-20JefferiesBuy
Competitors — type 1 diabetes
- LLYELI LILLY & Co$1094.4B · D3
- VRTXVERTEX PHARMACEUTICALS INC / MA$119.1B · D1
- SNYSanofi$52.5B · D1
- NKTRNEKTAR THERAPEUTICS$2.3B · D8
- IMCRImmunocore Holdings plc$1.8B · D1
- MNKDMANNKIND CORP$1.2B · D0
- SANASana Biotechnology, Inc.$860M · D7
- IPSCCentury Therapeutics, Inc.$381M · D6
- BMEABiomea Fusion, Inc.$90M · D6
- CELZCREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.$3M · D7
Recent news
- 2026-07-15SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment - Yahoo Finance
- 2026-07-08SAB Biotherapeutics (SABS) Edges Lower as Stock Tests Key Support Levels - Gap Up Stocks - dars.gov.et
- 2026-07-07Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial - Stock Titan
- 2026-07-05Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? - Yahoo Finance
- 2026-06-30Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance
- 2026-06-28SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Index - marketscreener.com
- 2026-06-26SABS Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-24Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.